Jump to content

ISTA Pharmaceuticals

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Magioladitis (talk | contribs) at 17:34, 14 February 2015 (clean up using AWB (10823)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

ISTA Pharmaceuticals, Inc.
Company typeSubsidiary
IndustryPharmaceuticals
Founded1992
HeadquartersIrvine, California
Key people
Vicente Anido Jr., Ph.D., President, Chief Executive Officer,

Glenn E. Davis, Vice President, Chief Compliance Officer, Marvin J. Garrett, Vice President, Regulatory Affairs, Quality & Compliance, Kathleen McGinley, Vice President, Human Resources & Corporate Services, Kirk McMullin, Vice President, Operations Timothy R. McNamara, PharmD, Vice President, Clinical Research & Medical Affairs

Tom Mitro, Vice President, Sales & Marketing
ProductsBromday, Bepreve, Xibrom, Istalol, Vitrase
Websitewww.istavision.com

ISTA Pharmaceuticals, Inc, was a US-based pharmaceutical company that specializes in ophthalmic pharmaceutical products and discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye.[1] ISTA was acquired by Bausch & Lomb on March 26, 2012.[2]

Products

  • Bromday (bromfenac ophthalmic solution) 0.09% for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction[3]
  • Bepreve (bepotastine besilate ophthalmic solution) 1.5% for the treatment of itching associated with signs and symptoms of allergic conjunctivitis[4]
  • Xibrom (bromfenac ophthalmic solution) 0.09% for the treatment of inflammation and pain following cataract surgery (no longer being manufactured as of February 2011)
  • Istalol (timolol maleate ophthalmic solution) 0.5% for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma[5]
  • Vitrase (hyaluronidase injection) Ovine, 200 USP Units/mL for use as an adjuvant to increase the absorption and ispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents[6]

References

  1. ^ "ISTA: Profile for ISTA Pharmaceuticals, Inc. - Yahoo! Finance". Finance.yahoo.com. Retrieved 2009-10-28.
  2. ^ "Bausch & Lomb to Buy ISTA Pharmaceuticals for $500 Million". The New York Times. Retrieved 2012-03-26.
  3. ^ http://www.istavision.com/products/bromday.html
  4. ^ http://www.bepreve.com/
  5. ^ http://www.istavision.com/products/istalol.html
  6. ^ http://www.istavision.com/products/vitrase.html


Stub icon

This United States manufacturing company–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=ISTA_Pharmaceuticals&oldid=647124767"